Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding, operational excellence, financial management, auditing, risk management and corporate governance.

The following persons have been elected:

  • Ulrik Spork, director of SporCon Lifescience Advisors and Salient Pharma, and chairman of the boards of Dansk Vækstkapital, Practio, MedTrace and Technolution. In addition, he has a number of further board and advisor roles.
  • Birgit Aagaard-Svendsen, board professional and currently on the boards of Aker Solutions, DNV GL Group, Prosafe and West of England, among others, for all of which she serves as the chairperson of the audit committee.

In addition, Rasmus Lundquist has decided to step down from his Board duties but will continue in his role as Chief Scientific Officer and member of Executive Management.

Niels Erik Holm and Rasmus Lundquist, founders of Reapplix, commented on the appointments: “We are extremely proud that we have been able to attract such strong profiles to Reapplix’s Board of Directors. We are confident that their knowledge will be invaluable to Reapplix as we accelerate the efforts to realise the huge market potential for our innovative approach to wound healing.”

Please refer to the board profiles for a full profile of each of the new board members, including past positions and special competencies.